Literature DB >> 27439500

Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.

Anna K Kozlowska1,2, Han-Ching Tseng1, Kawaljit Kaur1, Paytsar Topchyan1, Akihito Inagaki3,4, Vickie T Bui1, Noriyuki Kasahara3,4, Nicholas Cacalano5,6, Anahid Jewett7,8,9.   

Abstract

Natural killer (NK) cells are functionally suppressed in the glioblastoma multiforme (GBM) tumor microenvironment. We have recently shown that survival and differentiation of cancer stem-like cells (CSCs)/poorly differentiated tumors are controlled through two distinct phenotypes of cytotoxic and non-cytotoxic/split anergized NK cells, respectively. In this paper, we studied the function of NK cells against brain CSCs/poorly differentiated GBM and their NK cell-differentiated counterparts. Brain CSCs/poorly differentiated GBM, differentiated by split anergized NK supernatants (supernatants from NK cells treated with IL-2 + anti-CD16mAb) expressed higher levels of CD54, B7H1 and MHC-I and were killed less by the NK cells, whereas their CSCs/poorly differentiated counterparts were highly susceptible to NK cell lysis. Resistance to NK cells and differentiation of brain CSCs/poorly differentiated GBM by split anergized NK cells were mediated by interferon (IFN)-γ and tumor necrosis factor (TNF)-α. Brain CSCs/poorly differentiated GBM expressed low levels of TNFRs and IFN-γRs, and when differentiated and cultured with IL-2-treated NK cells, they induced increased secretion of pro-inflammatory cytokine interleukin (IL)-6 and chemokine IL-8 in the presence of decreased IFN-γ secretion. NK-induced differentiation of brain CSCs/poorly differentiated GBM cells was independent of the function of IL-6 and/or IL-8. The inability of NK cells to lyse GBM tumors and the presence of a sustained release of pro-inflammatory cytokines IL-6 and chemokine IL-8 in the presence of a decreased IFN-γ secretion may lead to the inadequacy of NK cells to differentiate GBM CSCs/poorly differentiated tumors, thus failing to control tumor growth.

Entities:  

Keywords:  Brain cancer stem cells; GBM; IFN-γ; Immunotherapy; NK cells

Mesh:

Substances:

Year:  2016        PMID: 27439500      PMCID: PMC4996719          DOI: 10.1007/s00262-016-1866-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  51 in total

1.  Long-term maintenance of brain tumor stem cell properties under at non-adherent and adherent culture conditions.

Authors:  Akihito Inagaki; Akio Soeda; Naoki Oka; Hideomi Kitajima; Jiro Nakagawa; Tsutomu Motohashi; Takahiro Kunisada; Toru Iwama
Journal:  Biochem Biophys Res Commun       Date:  2007-07-18       Impact factor: 3.575

2.  Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset.

Authors:  A Jewett; B Bonavida
Journal:  Cell Immunol       Date:  1995-01       Impact factor: 4.868

3.  Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells.

Authors:  A Jewett; M Cavalcanti; B Bonavida
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

Review 4.  Interleukin-8 and human cancer biology.

Authors:  K Xie
Journal:  Cytokine Growth Factor Rev       Date:  2001-12       Impact factor: 7.638

5.  Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors.

Authors:  S Miescher; M Stoeck; L Qiao; C Barras; L Barrelet; V von Fliedner
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

Review 6.  Natural killer cells as effectors of selection and differentiation of stem cells: role in resolution of inflammation.

Authors:  Anahid Jewett; Yan-gao Man; Nicholas Cacalano; Janko Kos; Han-Ching Tseng
Journal:  J Immunotoxicol       Date:  2014-02-27       Impact factor: 3.000

7.  Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8(77)).

Authors:  M Tada; K Suzuki; Y Yamakawa; Y Sawamura; S Sakuma; H Abe; E van Meir; N de Tribolet
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

8.  Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.

Authors:  Tsutomu Nakazawa; Mitsutoshi Nakamura; Young Soo Park; Yasushi Motoyama; Yasuo Hironaka; Fumihiko Nishimura; Ichiro Nakagawa; Shuichi Yamada; Ryosuke Matsuda; Kentaro Tamura; Tadashi Sugimoto; Yasuhiro Takeshima; Akiko Marutani; Takahiro Tsujimura; Noriko Ouji; Yukiteru Ouji; Masahide Yoshikawa; Hiroyuki Nakase
Journal:  J Neurooncol       Date:  2013-09-24       Impact factor: 4.130

9.  VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells.

Authors:  Naoki Oka; Akio Soeda; Akihito Inagaki; Masafumi Onodera; Hidekazu Maruyama; Akira Hara; Takahiro Kunisada; Hideki Mori; Toru Iwama
Journal:  Biochem Biophys Res Commun       Date:  2007-06-27       Impact factor: 3.575

10.  Induction of Split Anergy Conditions Natural Killer Cells to Promote Differentiation of Stem Cells through Cell-Cell Contact and Secreted Factors.

Authors:  Han-Ching Tseng; Vickie Bui; Yan-Gao Man; Nicholas Cacalano; Anahid Jewett
Journal:  Front Immunol       Date:  2014-06-19       Impact factor: 7.561

View more
  19 in total

1.  HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation.

Authors:  Tomas Hrbac; Alena Kopkova; Frantisek Siegl; Marek Vecera; Michaela Ruckova; Tomas Kazda; Radim Jancalek; Michal Hendrych; Marketa Hermanova; Vaclav Vybihal; Pavel Fadrus; Martin Smrcka; Filip Sokol; Vaclav Kubes; Radim Lipina; Ondrej Slaby; Leos Kren; Jiri Sana
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

2.  Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres.

Authors:  Barbara Breznik; Meng-Wei Ko; Christopher Tse; Po-Chun Chen; Emanuela Senjor; Bernarda Majc; Anamarija Habič; Nicolas Angelillis; Metka Novak; Vera Župunski; Jernej Mlakar; David Nathanson; Anahid Jewett
Journal:  Commun Biol       Date:  2022-05-10

Review 3.  Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.

Authors:  Jesus I Luna; Steven K Grossenbacher; William J Murphy; Robert J Canter
Journal:  Expert Opin Biol Ther       Date:  2016-12-23       Impact factor: 4.388

Review 4.  Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.

Authors:  Bernarda Majc; Metka Novak; Nataša Kopitar-Jerala; Anahid Jewett; Barbara Breznik
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

Review 5.  The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission.

Authors:  Jessica Kopenhaver; Madison Crutcher; Scott A Waldman; Adam E Snook
Journal:  Expert Opin Biol Ther       Date:  2021-05-24       Impact factor: 5.589

6.  Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs.

Authors:  Anna Karolina Kozlowska; Paytsar Topchyan; Kawaljit Kaur; Han-Ching Tseng; Antonia Teruel; Toru Hiraga; Anahid Jewett
Journal:  J Cancer       Date:  2017-02-11       Impact factor: 4.207

7.  Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice.

Authors:  Kawaljit Kaur; Hui-Hua Chang; Paytsar Topchyan; Jessica Morgan Cook; Andre Barkhordarian; Guido Eibl; Anahid Jewett
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

Review 8.  The Role of NK Cells and Innate Lymphoid Cells in Brain Cancer.

Authors:  Alexander James Sedgwick; Nazanin Ghazanfari; Patrick Constantinescu; Theo Mantamadiotis; Alexander David Barrow
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

9.  Cystatin F acts as a mediator of immune suppression in glioblastoma.

Authors:  Emanuela Senjor; Milica Perišić Nanut; Barbara Breznik; Ana Mitrović; Jernej Mlakar; Ana Rotter; Andrej Porčnik; Tamara Lah Turnšek; Janko Kos
Journal:  Cell Oncol (Dordr)       Date:  2021-06-29       Impact factor: 6.730

10.  Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma.

Authors:  Camilla Bjørnbak Holst; Ib Jarle Christensen; Kristoffer Vitting-Seerup; Jane Skjøth-Rasmussen; Petra Hamerlik; Hans Skovgaard Poulsen; Julia Sidenius Johansen
Journal:  Neurooncol Adv       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.